Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03496649
Other study ID # CHUBX2014/21
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date May 2, 2019
Est. completion date August 2, 2020

Study information

Verified date May 2019
Source University Hospital, Bordeaux
Contact Mathieu De Seze, PH
Phone 0556795516
Email mathieu.de-seze@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pubalgia is a pain syndrome located in the groin area. This syndrome is mainly described in young male athletes and typically affect the superficial muscles defining the boundaries of the femoral triangle, i.e. gracilis, pectineus, adductor brevis and especially adductor longus, and less commonly the deep muscles.

Clinically, the pain is located in the inner aspect of the thigh, where the tendons attach onto the pubic symphysis. It is usually unilateral, and sometimes associated with neuropathic pain suggestive of obturator nerve irritation.

There is no official recommendation or expert consensus on the management of pubalgia. However, a few protocols recommend a period of rest with Non-Inflammatory Anti-Steroidien Drugs (NSAIDs), icing and massages, as well as rehabilitation with passive stretching and muscle reinforcement.

The use of botulinum toxin type A could be an option in cases of treatment failure. However, a feasibility study must be performed beforehand, and if results are positive, a controlled study on a larger cohort could be conducted.

The major potential impact is a great effective pain relief for patients with neurological diseases.


Description:

The incidence of pubalgia in the literature varies, with large series reporting an incidence close to 5-10%, representing 15 to 18% of all injuries.

Recurrences are also common, affecting 30 to 35% of cases.

Once other differential diagnoses (such as spondylarthropathy, colorectal cancer, kidney disease…) have been ruled out, athletic pubalgia is typically divided into three main categories based on the site of the injury:

- Abdominal wall, the most common form, representing 38 to 50% of all cases;

- Pubic symphysis due to osteoarthropathy of the pubic bone caused by repetitive stress injury, accounting for 10 to 15% of all cases of pubalgia;

- Adductor tendons, on which this study focuses, representing 22 to 38% of all cases of pubalgia, caused by repetitive tractions on the tendon insertions.

There is no official recommendation or expert consensus on the management of pubalgia. However, a few protocols recommend a period of rest with Non-Inflammatory Anti-Steroidien Drugs (NSAIDs), icing and massages, as well as rehabilitation with passive stretching and muscle reinforcement.

Neuromuscular reprogramming is then performed to stabilise the pelvis, followed by a progressive resumption of sporting activities, guided by the pain level.

Generally, 70 to 85% of patients are able to resume their sporting activities with this management protocol.

In 15 to 20% of cases of essential adductor tendinopathy, symptoms do not improve and the only currently validated solution is then a tenotomy, sometimes combined with partial tendon release in recurring cases.

Recent studies showed that the use of botulinum toxin type A (BTA) produces fairly positive results in chronic tendinopathies, such as epicondylitis. However, the efficacy of BTA injections in adductor tendinopathies has not been demonstrated consistently and a feasibility study must be conducted to address this question.

The hypothetical benefit of BTA in adductor tendinopathies is based on the toxin's known effects:

1. a purely analgesic effect, which reduces pain in the injected area within a few days. This type of chronic tendinopathy does not involve inflammation. The pain in such cases is most likely due to the action of neurotransmitters such as substance P and calcitonin gene-related peptide (CGRP). As BTA is known to inhibit the secretion of these neurotransmitters, this mechanism could explain the toxin's specific analgesic effect.

2. a muscle relaxant effect due to its action on the motor endplate, which reaches its maximum 6 weeks after the injection, and lasts 3 to 6 months.

The resulting muscle relaxation helps improve healing of the damaged tendon, and provides sustained analgesia.

A series including 39 cases showed that botulinum toxin is effective on hip adductor muscles following total hip arthroplasty, providing reduced muscle contracture and improved hip mobility without side effects.

The use of botulinum toxin type A could be an option in cases of treatment failure. However, a feasibility study must be performed beforehand, and if results are positive, a study on a larger cohort could be conducted.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date August 2, 2020
Est. primary completion date August 2, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Male or female patient 18 to 65 years old

- Patient with episode of adductor tendinopathy, refractory to appropriate medical treatment lasting 3 months

- Tendinopathy confirmed by clinical investigation, echography and MRI.

- Patient naïve to intramuscular botulinum toxin injections

- Patient able to self-evaluate pain on a VAS

- Intensity of exercise-induced pain > 5 on a VAS of 10

- Patient able to provide a signed informed consent freely for the study protocol and data collection

Exclusion Criteria:

- Subject participating or having participated in the last 3 months in another study which could interfere with the objective of the study

- Neuralgia

- Acute muscle injury

- Progressive disease at the time of inclusion

- Anticoagulant treatment: heparin administered with an electrical syringe or AVK therapy with effective doses

Exclusion criteria related to Dysport injection (botulinum toxin type A) :

- Known hypersensitivity to botulinum toxin type A or to any of the components in the formulation (20% human albumin solution, lactose monohydrate)

- Subject with a significant deficit of clinical or subclinical neuromuscular transmission (myasthenia or Lambert-Eaton syndrome)

- Treatment that directly or indirectly interferes with neuromuscular transmission (aminoglycosides, curare, anticholinesterase, aminoquinoline, cyclosporine, etc.)

- Previous surgery with curarisation less than a month ago

- History of neuromuscular disorders

- Pregnant or breastfeeding woman

- Women of child-bearing potential not using contraceptive methods during the study duration

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dysport 500 Unit Powder for Injection
Dysport administered by intramuscular injection

Locations

Country Name City State
France CHU de Bordeaux Bordeaux

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Bordeaux Ipsen

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients with a pain reduction (VAS) Proportion of patients with a pain reduction of over 50% compared to baseline, as shown by the average pain intensity measured between D80 and D90 on a Visual Analogic Scale (VAS) from 0 to 10 (0 = no pain; 10 = worst pain imaginable).
Pain intensity will be daily collected by the patient in his patient's diary.
Between Day 80 and Day 90
Secondary Exercise-induced pain intensity (VAS) Average intensity of exercise-induced pain evaluated daily by the patient on a VAS type numerical scale Daily between Day 0 and Day 90
Secondary Pain relief Percentage of patients with over 50% pain relief compared to baseline On Day 30 and Day 90
Secondary Goal Attainment Scaling (GAS) Percentage of patients with over 50% GAS objective reached On Day 30 and Day 90
Secondary Blazina clinical classification system Improvement of at least 1 point on the Blazina clinical classification system in 50% of patients On Day 30 and Day 90
Secondary Adductor strength Preservation or improvement of adductor strength measured with a dynamometer and resumption of sport activity (Tegner activity level scale) in 50% of patients On Day 30 and Day 90
Secondary Cure rate based on patients' self-evaluation Percentage of patients with over 50% cure rate based on the patients' self-evaluation of the improvement of their condition On Day 30 and Day 90
Secondary Cure rate based on physician's evaluation Percentage of patients with over 50% cure rate based on the physicians' evaluation of the patients' improvement On Day 30 and Day 90
Secondary Treatment Percentage of patients not asking for further treatment On Day 30 and Day 90
Secondary Pain diary Determination of a break point on the pain intensity graph plotted by the physician, based on the pain diary completed by the patient. On Day 30 and Day 90
Secondary HAGOS self-reported questionnaire Improvement on the 6 dimensions of the HAGOS self-reported questionnaire On Day 30 and Day 90
Secondary Tolerance Tolerance evaluation: description and frequency of adverse effects. Day 1, Day 7, Day 14, Day 30, Day 90
See also
  Status Clinical Trial Phase
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT03307499 - NeoPatch Used as Adjunct in Foot and Ankle Tendon Surgery N/A
Completed NCT02499484 - Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy N/A
Completed NCT01944150 - Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis N/A
Recruiting NCT04578418 - Effect of Collagen Supplementation on Tendinopathy N/A
Completed NCT03262181 - The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy N/A
Completed NCT03502434 - A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers Phase 1
Recruiting NCT04278833 - Comparative Effectiveness of Particulate Versus Nonparticulate Steroid Injections for Musculoskeletal Conditions Phase 4
Completed NCT05897866 - Sayed Issa's Hybrid Shoulder Arthroscopic-Open Surgical Management (HSSM) N/A
Recruiting NCT05603468 - Effect of PRP vs Corticosteroid in Rotator Cuff Tendinopathy Subtypes in Arthroscopic Repair Phase 4
Terminated NCT01544244 - The Global Shoulder Concept (GSC) Method Versus Classic Physical Therapy for Shoulder Tendinitis N/A
Recruiting NCT04144946 - Identification of Early Changes in Patellar Tendinopathy Using Ultra-high Field Strength MRI
Terminated NCT02978833 - Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy Phase 4
Completed NCT03229291 - A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects Phase 1
Recruiting NCT06056440 - Efficacy of a Physical Rehabilitation Program Using Virtual Reality in Patients With Chronic Tendinopathy (Virtendon-Rehab) N/A
Recruiting NCT04058509 - Clinical Predictors of Extracorporal Shockwave Therapy Efficacy in Patients Presenting With Lateral Hip Pain N/A
Withdrawn NCT02981394 - Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions
Active, not recruiting NCT02600910 - Natural History of Shoulder Pathology in Manual Wheelchair Users
Completed NCT04793971 - Minimal Invasive Treatment of Achilles Tendinopathy: Focus on Percutaneous Release (Maffulli)
Not yet recruiting NCT01225497 - Eccentric Exercise for Chronic Mid-portion Achilles Tendinopathy N/A